What Is Biostatistics? Its Role and Key Applications

Biostatistics is the branch of statistics devoted to collecting, analyzing, and interpreting data from the life sciences and health care. It sits at the center of nearly every medical advance you hear about: when a news headline says a new drug “works,” a biostatistician designed the trial that tested it, chose how many patients to enroll, decided how to handle the ones who dropped out, and ran the analysis that determined whether the drug’s benefit was real or a fluke. The field stretches well beyond drug trials, though, reaching into disease surveillance, diagnostic testing, genomics, environmental health, wildlife conservation, and the algorithms that increasingly shape medical decisions.

Why Clinical Trials Need Biostatistics From the Start

A clinical trial is only as good as its design, and design is where biostatisticians earn their keep. One of the most consequential early decisions is sample size. Enroll too few patients and the trial may miss a real treatment effect; enroll too many and you waste time, money, and participant goodwill on a question you could have answered sooner. Getting this wrong has real consequences: a miscalculated sample size can lead to rejection of genuinely useful treatments or, worse, approval of ones that do not actually help.¹

Beyond sample size, biostatisticians determine how patients get assigned to treatment and control groups, how outcomes get measured, and which statistical tests will be applied before anyone looks at the data. That last point matters more than it sounds. Pre-specifying the analysis plan prevents researchers from unconsciously (or consciously) cherry-picking whichever method yields the most flattering result. The entire credibility of randomized trials rests on this kind of statistical discipline.

Randomized controlled trials are considered the gold standard for establishing cause and effect, but they are not always possible. You cannot randomly assign people to smoke for twenty years to study lung cancer. In those situations, researchers rely on observational studies, which come with their own statistical headaches, most notably selection bias. Both study types have genuine strengths and genuine limitations, and a biostatistician’s job includes knowing when each is appropriate and how to interpret results accordingly.²

Untangling Confounding Variables

Imagine a study finds that coffee drinkers have higher rates of heart disease. Does coffee cause heart problems, or do coffee drinkers also tend to smoke more, sleep less, and eat worse? The lurking third factor that distorts the apparent relationship between two variables is called a confounder, and dealing with confounders is one of biostatistics’ core preoccupations.

Some confounders can be handled during study design through randomization, restriction (only enrolling nonsmokers, for instance), or matching patients on key characteristics. But when those design-phase controls are not feasible, biostatisticians turn to statistical methods after data collection. Regression models are the workhorse here: they let researchers mathematically hold confounders steady while examining the relationship they actually care about.³ More advanced approaches like propensity score methods have become standard in studies based on large health care databases, where true randomization is impossible because the data come from routine clinical care rather than a controlled experiment.⁴

None of these techniques eliminate confounding perfectly, and unknown confounders can always lurk in the data. But the difference between a study that tries to control for confounders and one that does not is often the difference between a useful finding and a misleading one.

Measuring How Well a Diagnostic Test Performs

When your doctor orders a blood test or imaging scan, two questions matter most: how good is this test at catching the disease when it is there, and how good is it at correctly clearing people who do not have it? Biostatisticians formalize these questions as sensitivity and specificity.⁵ A test with high sensitivity rarely misses true cases; a test with high specificity rarely raises false alarms. No test is perfect on both counts, so there is always a trade-off.

To visualize that trade-off, researchers plot something called a receiver operating characteristic (ROC) curve, which maps sensitivity against the false-positive rate across every possible threshold for calling a result “positive.” The area under that curve gives a single number summarizing overall test accuracy. When multiple studies evaluate the same test and produce different curves, biostatisticians can combine them into a summary ROC curve through meta-analysis, providing a pooled estimate of performance that is more reliable than any single study alone.⁶

This matters practically because regulators and hospitals use these analyses to decide which tests to approve, which to recommend as screening tools, and where to set the cutoff for a positive result. A mammography program, a rapid COVID test, a tumor biomarker: each went through this kind of statistical evaluation before reaching you.

Tracking and Predicting Epidemics

Biostatistics played a visible, public-facing role during the COVID-19 pandemic, but the field had been central to infectious disease modeling for decades before that. Epidemiological models that estimate how fast a disease will spread, how many people it will infect, and how effective interventions might be all depend on statistical methods for fitting models to messy, incomplete, real-world data.⁷

During the 2014 Ebola outbreak in Sierra Leone, for example, researchers used a compartmental model that classified people as susceptible, exposed, infectious, or removed, and estimated the disease transmission rate using flexible statistical curves. The approach allowed them to estimate the effective reproduction number even when the available data were irregular and likely undercounted actual cases.⁸ That kind of analysis directly informs public health decisions about quarantine zones, resource allocation, and vaccination campaigns.

Quantifying the relationship between an exposure and a health outcome is also central to epidemiology more broadly. Whether studying the link between obesity and diabetes or between a workplace chemical and cancer, biostatisticians help determine whether the association is likely causal and how strong it is.⁹

Genomics and the Multiple-Testing Problem

Modern genomic studies routinely measure the activity of tens of thousands of genes at once, looking for the ones associated with a particular disease. The statistical challenge is staggering: if you test 20,000 genes for an association, roughly 1,000 will appear “significant” by pure chance at the conventional threshold. Biostatisticians developed methods to control the false discovery rate, keeping the number of spurious findings manageable without being so conservative that real signals get buried.

Researchers continue to refine these methods. A recent study proposed modified procedures for controlling false discoveries specifically under conditions where gene expression data are correlated with one another, as they often are in practice. When applied to colorectal cancer gene expression data, the modified procedures produced more efficient predictive models than the standard approaches.¹⁰ This is not an academic exercise: the genes identified through these methods become candidates for diagnostic biomarkers and drug targets. Getting the statistics wrong means either chasing genes that have nothing to do with the disease or overlooking ones that do.

Environmental Health and Air Pollution

Some of the most influential biostatistical work has dealt with environmental exposures, particularly air pollution. The Harvard Six Cities Study, which followed thousands of adults across six U.S. cities for years, became a landmark in demonstrating the health effects of particulate air pollution. The study required cutting-edge methods for longitudinal and repeated-measures data, developed through close collaboration between epidemiologists and biostatisticians.¹¹

Air pollution research is statistically tricky because people are never exposed to just one pollutant. They breathe a mix of particulate matter, ozone, nitrogen dioxide, and other substances simultaneously. Researchers have developed at least five broad classes of statistical approaches to tease apart the effects of multiple pollutants at once, ranging from simple additive models to nonparametric methods that make fewer assumptions about how pollutants interact.¹² The resulting concentration-response functions, which describe how health risk changes as pollution levels rise, feed directly into regulatory standards and health impact assessments.¹³

The P-Value Problem

If there is one biostatistical concept that has seeped into popular awareness, it is the p-value, the number that supposedly tells you whether a result is “statistically significant.” The conventional cutoff of 0.05 has been treated as a bright line separating real findings from noise for decades. But biostatisticians themselves have grown increasingly vocal about how often p-values are misused or misunderstood. A growing body of literature identifies this misuse as a major contributor to the reproducibility crisis in biomedical research, where findings published in respected journals fail to hold up when other labs try to replicate them.¹⁴

The problems are several. A p-value does not tell you the probability that your hypothesis is true. It does not tell you how large or important an effect is. And with enormous datasets like electronic health records or genomic databases, even trivially small effects can cross the 0.05 threshold simply because the sample is big enough to detect anything. Some researchers have argued for supplementing or replacing the 0.05 threshold with approaches like meta-analyses, data sharing, and cost-effectiveness analyses, which provide a more complete picture of whether a finding is real and worth acting on.¹⁵

What Happens When Patients Drop Out

Missing data is one of the least glamorous but most consequential problems in biostatistics. In a typical clinical trial, some patients stop taking the study drug, miss follow-up visits, or withdraw entirely. If those dropouts are not random (say, sicker patients tend to quit because of side effects), simply analyzing whoever is left can produce badly skewed results.

The standard approach is intention-to-treat analysis, which keeps every enrolled patient in the analysis regardless of whether they finished the protocol. But even this approach raises complicated questions. A study of cocaine dependence treatment illustrated the issue by analyzing the same trial data three different ways: one using data only up to the point of dropout, one using the full intended duration, and one incorporating treatment retention as a variable. The conclusions about which treatment worked better shifted depending on which strategy was used.¹⁶

When the reason data is missing cannot be assumed to be random, biostatisticians use conservative imputation approaches that essentially fill in the gaps with cautious assumptions, such as assuming that dropouts reverted to their baseline condition.¹⁷ The point is not that there is one right answer but that ignoring the problem entirely almost guarantees a wrong one.

Algorithmic Bias in Health Care

As hospitals and insurers increasingly use algorithms to allocate care, biostatistics has bumped up against questions of fairness. A widely cited study found that a commercial algorithm used to identify patients who needed extra medical attention was systematically biased against Black patients. At any given risk score, Black patients were considerably sicker than white patients with the same score. The root cause was a data choice: the algorithm predicted health care costs rather than actual illness, and because Black patients historically had less access to care, less money had been spent on them, making them look healthier to the algorithm than they actually were. Fixing that bias would have nearly tripled the share of Black patients flagged for additional help, from roughly 18% to about 47%.¹⁸

The problem extends beyond that one algorithm. A review of cancer prediction models found that only about 22% used demographically diverse patient groups, and when race was reported, about 88% of participants were white. The models performed best for white patients and worst for older adults over 70, who ironically carry the highest cancer burden. Attempted fixes like resampling and adversarial learning showed inconsistent results, with no single method reliably improving fairness across all datasets.¹⁹ Biostatisticians are increasingly being called on not just to build accurate models but to audit them for the ways data choices can bake in inequity.

Machine Learning and Traditional Statistics Working Together

The rise of machine learning has raised a question in medical research: should we stick with traditional statistical models or switch to newer algorithms? The honest answer from the literature is that neither consistently outperforms the other, and combining them looks promising. A systematic review of disease prediction models that integrated machine learning with statistical methods found that the hybrid models generally outperformed either approach alone, with area-under-the-curve scores consistently above 0.75.²⁰

Traditional statistical methods are often more interpretable: a clinician can look at a regression model and understand which variables are driving a prediction and by how much. Machine learning models tend to be better at detecting complex, nonlinear patterns in high-dimensional data, like the kind found in electronic health records. Researchers are now exploring how to use electronic health records from real-world clinical settings to build predictive models that can forecast things like future lab test results for individual patients.²¹ The statistical foundation remains essential even when the algorithms get fancier, because questions about bias, confounding, and generalizability do not disappear just because a neural network is doing the calculations.

Real-World Evidence From Electronic Health Records

Electronic health records have become an enormous data resource for medical research, offering real-time information from actual clinical practice rather than the controlled setting of a trial. But the data come with biases that biostatisticians have to navigate carefully. Records may be incomplete, coded inconsistently, or skewed toward patients who seek care more frequently. A patient who sees a doctor twelve times a year will generate far more data points than one who visits once, but that does not mean the frequent visitor is sicker in ways that matter for a given study question.²²

Despite these challenges, the appeal is obvious. Randomized trials enroll hundreds or at most a few thousand patients and run for a defined period. Electronic health records contain data on millions of patients over years of care, making them valuable for studying rare outcomes, long-term effects, and subgroups too small to study in a trial. The biostatistical methods for analyzing this data are evolving rapidly, drawing on techniques for handling confounding in observational data, dealing with missing and irregular measurements, and adjusting for the various biases built into how health records get created.

Biostatistics at the Regulatory Table

When a pharmaceutical company submits a new drug application to the U.S. Food and Drug Administration, biostatisticians on the FDA’s side independently review the statistical methods and results. The FDA’s Office of Biostatistics within the Center for Drug Evaluation and Research conducts its own research on statistical methodology and applies that work directly to the regulatory review process. Their portfolio spans clinical trial design, Bayesian statistics, meta-analysis, benefit-risk assessment, and bioequivalence testing, among other areas.²³

This regulatory role is easy to overlook, but it is one of the most consequential applications of biostatistics. A disagreement between a company’s biostatisticians and the FDA’s over something as seemingly technical as the handling of missing data or the choice of primary endpoint can determine whether a drug reaches the market. The FDA’s independent statistical review acts as a check on the analyses submitted by companies that have a financial stake in the outcome.

Beyond Human Health

Biostatistics is not limited to medicine. Ecologists and conservation biologists use many of the same statistical frameworks to study animal populations. Multistate models, for instance, let researchers estimate wildlife population sizes and track changes over time even when the data are incomplete, as they almost always are in field studies. A 25-year study of black-throated blue warblers at Hubbard Brook Experimental Forest in New Hampshire used these methods to estimate population abundance and recruitment rates, producing results consistent with earlier capture-recapture studies.²⁴

Similar methods have been applied to declining European grey partridge populations, where researchers used generalized linear mixed models on nearly two decades of transect count data to assess population trends and synchrony between local subpopulations.²⁵ Conservation decisions about habitat management and hunting regulations flow directly from these analyses. The statistical challenges are strikingly parallel to those in human epidemiology: incomplete data, confounding environmental variables, populations that move and change, and the need to make policy decisions before the evidence is perfectly clean.

Health Economics and Cost-Effectiveness

Health care systems operate under finite budgets, and biostatistics helps answer a question that is uncomfortable but unavoidable: is this treatment worth the money? Cost-effectiveness analysis uses statistical methods to compare the costs and health outcomes of different interventions. A treatment that extends life by six months at modest cost might be judged differently from one that extends it by the same amount at enormous expense.

The statistical wrinkles here are specific to the domain. Cost data are notoriously skewed, with a small number of very expensive patients pulling the average upward. And when a study follows patients over time, some inevitably drop out or die before the study ends, censoring their cost data before the full picture is captured. Specialized methods exist to estimate mean costs and cost-effectiveness ratios under these conditions, handling both total-cost snapshots and longitudinal cost histories.²⁶ These analyses inform decisions made by insurers, hospital systems, and national health services about which treatments to cover and which to consider too expensive relative to their benefit.